TVGNTevogen Bio Holdings Inc.
The Read
TVGN stock historically moves about 19% on earnings but surged nearly 39% on its May 2026 Q1 report due to a $3 million private investment and improved operating outlook, while its June 29 earnings reaction is not documented.
The schedule
- Thu15Oct
Management's strategic pivot to generate non-dilutive capital through Tevogen.AI acquisitions and partnerships faces a critical update window.
- Thu12Nov
Trial updates on the lead T-cell therapeutic candidate, where efficacy signals must justify the high R&D expenditures.
- Tue15Dec
Early feedback from the FDA regarding IND-enabling studies or early-stage trial designs for the expanded oncology pipeline.
- Thu11Feb
The Q3 print will be the proving ground for whether the Tevogen.AI initiative has begun to offset the clinical pipeline's high cash burn.
- Wed12May
Full-year results will outline the cash position exiting 2026 and set expectations for clinical R&D spending into the new fiscal year.
- Fri14May
The Q1 2027 report will serve as a critical going-concern and runway assessment for the upcoming clinical milestones.
Past
- Wed30Sep
The need to secure further capital before Q4 to maintain operations and fund clinical milestones may force a dilutive equity offering.
- Thu13Aug
Actual outcome: Bull · $6.87 at outcome
Tevogen reported Q2 EPS of -$1.61, exactly in line with consensus estimates. The stock rallied as investors reacted positively to updates on the company's cash burn management following its recent $3M infusion and early details regarding the Tevogen.AI commercialization strategy. These developments provided confidence in the company's near-term operational runway and strategic direction, driving shares higher.
Tevogen's Q2 print will heavily feature cash burn dynamics against its recent $3M cash infusion and early guidance on Tevogen.AI's commercialization strategy.
- Fri15May
Actual outcome: Bull · $10.48 at outcome
Tevogen reported in-line EPS of -$1.20, but the stock surged well past the bull target due to positive strategic and financing developments. A $3 million private investment priced at an $8 per share premium bolstered the company's cash runway, while a shareholder letter highlighting improved operating performance and the pursuit of revenue-generating acquisitions fueled investor optimism.
Quarterly earnings evaluating the immediate post-split financial structure and the liquidity runway amid ongoing clinical operations.
- Fri10Apr
Actual outcome: Bull · $6.44 at outcome
TVGN successfully implemented the 1-for-50 reverse split, effectively curing its NASDAQ non-compliance by maintaining a share price well above the $1.00 minimum requirement. While the stock experienced typical post-split technical selling from its theoretical $10.00 opening, it stabilized above the $4.00 bear floor, signaling that the immediate risk of delisting has been mitigated and providing a more stable structure for institutional investment.
Execution of the reverse stock split to cure NASDAQ non-compliance (assuming a 1-for-50 ratio, which would theoretically yield a $10.00 price). Post-split, the stock almost always drops significantly from its theoretical value due to technical selling and perception issues.
